Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Double-Dummy, Active-controlled, Parallel-group, Multicenter Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Subjects With Acute Coronary Syndrome

Next Previous
Trial Profile

A Randomized, Double-Blind, Double-Dummy, Active-controlled, Parallel-group, Multicenter Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Subjects With Acute Coronary Syndrome

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Acute coronary syndromes
  • Focus Adverse reactions
  • Acronyms GEMINI 1 ACS; GEMINI ACS 1
  • Sponsors Janssen Research & Development

Most Recent Events

  • 01 Sep 2020 Results of integrated analysis from six clinical studies: ATLAS-1, ATLAS-2, COMPASS, COMMANDER HF, GEMINI ACS1 and PIONEER AF-PCI presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology
  • 12 Mar 2018 Results of pooled analysis of ATLAS-ACS-TIMI-46, ATLAS-ACS-2-TIMI-51, GEMINI-ACS-1, and COMPASS trial comparing efficacy and safety of Rivaroxaban based dual pathway antithrombotic therapy Vs dual antiplatelet therapy presented at the 67th Annual Scientific Session of the American College of Cardiology
  • 18 Mar 2017 According to a Janssen Pharmaceuticals media release, this trial is part of Janssen's EXPLORER clinical research program.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top